u/Away_Definition5829

$22M cash vs $33M market cap; exclusive GE HealthCare contract generates $6-7M annually; management clearing two losing segments. Net cash covers two-thirds of market cap, making the profitable core contract essentially free; cleanup could unlock hidden value. Deep value play with cash backing and a catalyst from divestitures. OTC listing, low liquidity, remaining losses persist.

12x FCF, 20% compounding trips growth, 50m Uber One members, CFO bought $1.6m at $71.25. AV disruption fears are overdone; platform economics and insider buying suggest current valuation is attractive. A quality growth business priced as a value stock, with a clear insider signal. AV competition intensifies; regulatory changes; macro slowdown affecting ride demand.

Nike is down 75% from its peak and insiders are currently buying the stock. Despite flat revenue and lost shelf space to competitors, insider buying signals a bottom and a strategic reversal. The massive drawdown presents a value opportunity as the company begins its turnaround. Turnaround fails to regain market share from Hoka and On.

Novo Nordisk is down 42% over twelve months and trades at 11 times trailing earnings. The market is pricing in a permanent impairment due to US GLP-1 price resets, which is an overreaction. The extremely low valuation multiple for a dominant pharmaceutical company offers a strong margin of safety. GLP-1 price resets severely impact long-term profitability.

Altyn Gold has an enterprise value approaching zero, with inventory carried at one-third of the spot price. The massive disconnect between the book value of inventory and current gold prices creates an arbitrage-like valuation gap, alongside plans to double production by 2027. A "TOP PICK" deep-value play where liquidating inventory at market prices would nearly cover the acquisition cost of the entire company. Geopolitical and operational risks in Kazakhstan, plus high insider ownership (65%) limiting minority shareholder influence.

Gravity has a $452m market cap with $434m in net cash and trades at an 8x P/E. The enterprise value is essentially zero, meaning the core Ragnarok franchise, royalties, and new Chinese mobile approvals are completely unpriced by the market. A deep-value "TOP PICK" offering a massive margin of safety with a newly initiated dividend and clear growth catalysts. Concentration risk in a single gaming franchise (Ragnarok) and potential regulatory shifts in the Chinese gaming market.

Netflix generated $6.6B free cash flow in H1 2026, has 33% operating margins, 45% penetration of 800M households, and $27.1B remaining buyback capacity. The DCF model from one write‑up shows 22% upside; ads, gaming, and live events are barely monetized yet – further growth drivers. Strong free cash flow and under‑penetrated ancillary revenue streams support a re‑rating. Competition from streaming rivals, subscriber saturation, or a recession could slow growth. PETS LN - LONG | confidence: 0.70 | sentiment: +0.60 Speaker: u/Away_Definition5829 Thesis: Pets at Home trades at 12x earnings and yields 9% free cash flow; vet services generate 80% of group profit. COVID‑era pets are now entering their most expensive life stage (middle age), driving recurring vet revenue, while the overall valuation remains cheap. A defensive, recession‑resilient business with a high‑margin service component and a low multiple – attractive for value‑oriented investors. Slowdown in pet ownership growth, regulatory changes in veterinary practice, or increased competition.

Down 50% YTD on first revenue decline in eight quarters, but pre-tax income guidance still 7-16% higher; zero debt, $27M cash, and 25% short interest. High short interest and low market cap create squeeze potential, while the core business remains profitable and debt-free, offering asymmetric upside. Recovery trade with strong fundamentals and a short-squeeze catalyst. Continued revenue decline, consumer spending slowdown, further earnings misses.

Fairfax has compounded book value at 15-20% annually; trades at 1.35x book with aggressive buybacks and upcoming Poseidon IPO. Near-term IPO catalyst could rerate the stock as market recognizes value creation; buybacks boost per-share value. High-quality compounder at reasonable price with a specific catalyst. Insurance cycle downturn, IPO delays, investment losses.

Microsoft shed $500B market cap on AI capex fears, now at 22x trailing P/E; durable platform lock-in argued. Market overestimates spending cycle risk; Microsoft's entrenched enterprise position ensures long-term value. Value opportunity in mega-cap tech with stable earnings and a low multiple. AI capex continues to erode margins, competition, regulatory scrutiny.

Losing Apple modem business, but automotive division scaled from $500M to $6B; humanoid robot partnerships provide free option at 20x earnings. Market overreacts to Apple loss while ignoring diversification into auto and robotics; current valuation does not price new growth. Contrarian play on hidden growth vectors with a reasonable valuation. Apple modem loss deeper than expected, robot monetization slow, cyclical downturn.

Kaspi.kz trades at 6.8x P/E with an 8% dividend, Tencent as a strategic investor, and 23% founder ownership. The super-app model is undervalued relative to peers, and the Turkey expansion provides a new growth leg. A compelling value play with high insider alignment and a strong dividend yield, supported by a major tech partner. Kazakhstan political/regulatory risk; Turkey expansion may underperform; fintech competition.

Block’s headline 101% revenue growth strips to only 17% organic once Bitcoin is excluded, and a $240M DOJ accrual remains unresolved. The market is pricing the artificial Bitcoin-driven growth as sustainable, ignoring legal overhang and slowing core business. Short Block because the misleading growth narrative and unresolved litigation make the current valuation unsustainable. Bitcoin price rally could boost sentiment; DOJ settlement could be lower than expected; PayPal underperformance could keep Block bid.

Zoetis is down 54% from its 2022 peak, trading at decade-low multiples, yet remains the clear leader in animal health. The market fears GLP-1 drugs will eliminate pet care spending, but this is overblown; pet healthcare demand is resilient. Buy Zoetis at depressed levels for a long-term compounder with a strong moat and a temporary fear-based discount. GLP-1 drugs could reduce pet obesity-related spending; new animal health competitors; regulatory changes.

eDreams has 7.9M Prime subscribers, EBITDA up 74% over nine months, and management buying stock at P/E 5.1x. The -64% drawdown creates a deep value entry point; the underlying subscription business is growing rapidly while the market remains focused on past losses. At 5.1x P/E with accelerating EBITDA and insider buying, the risk/reward strongly favors a long position. High net debt, competitive pressure from Booking/Expedia, or a slowdown in travel demand could invalidate the thesis. 1913 HK - LONG | confidence: 0.85 | sentiment: +0.80 Speaker: u/Away_Definition5829 Thesis: Prada trades at 9x EV/EBIT while luxury peers trade 16–25x; Miu Miu is growing 60%+ and the family controls 80% of shares. The valuation discount implies brand impairment, but Miu Miu’s explosive growth and strong free cash flow prove the brands are intact and gaining share. A luxury conglomerate with pricing power, family stewardship, and a clear growth driver (Miu Miu) priced at a 50%+ discount to peers is a compelling long. Slowdown in Chinese luxury demand, FX headwinds, or brand dilution could narrow the arbitrage.